Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2612-2618

  Garcia Contreras, L ^a,c   Muttil, Pavan ^a,d   Fallon, John K ^a   Kabadi, Mohan ^b   Gerety, Robert ^b   Hickey, Anthony J ^a,b,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Medicine in Need   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; EXPERIMENTAL GUINEA PIG; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; POWDER; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CAPREOMYCIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GUINEA PIGS; INJECTIONS, INTRAMUSCULAR; LUNG; MALE; MYCOBACTERIUM TUBERCULOSIS; PARTICLE SIZE; POWDERS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84860109542     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06145-11     Document Type: Article

References (22)

1. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. 2010. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2. Second line drugs. J. Bras. Pneumol. 36:641-656.
2. Black HR, Griffith RS, Peabody AM. 1966. Absorption, excretion, and metabolism of capreomycin in normal and diseased states. Ann. N. Y. Acad. Sci. 135:974-982.
3. Donomae I. 1966. Capreomycin in the treatment of pulmonary tuberculosis. Ann. N. Y. Acad. Sci. 135:1011-1038.
4. Fiegel J, et al. 2008. Preparation and in vivo evaluation of dry powder for inhalation of capreomycin. Pharm. Res. 25:805-811. (Pubitemid 351661830)
5. Garcia-Contreras L, et al. 2007. Inhaled large porous particles of capreo- mycin for the treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51:2830-2836. (Pubitemid 47206218)
6. Garcia-Contreras L, et al. 2001. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm. Res. 18:1685-1693. (Pubitemid 34020423)
7. Garfield J, Jones J, Cohen N, Daly J, McClement J. 1966. The auditory, vestibular and renal effects of capreomycin in humans. Ann. N. Y. Acad. Sci. 135:1039-1046.
8. Gothi D, Joshi JM. 2011. Resistant TB: newer drugs and community approach. Recent Pat. Antiinfect. Drug Discov. 6:27-37.
9. Gyselen A, Verbist L, Prignot J, Cosemans J. 1965. Capreomycin in the re-treatment of patients with pulmonary tuberculosis. Tubercle 46:243-249.
10. Harkness JE, Wagner JE. 1995. The biology and medicine of rabbits and rodents. Williams and Wilkins, Media, PA.
11. Hedt BL, Laufer MK, Cohen T. 2011. Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria. Am. J. Trop. Med. Hyg. 84:192-199.
12. Heifets L, Simon J, Pham V. 2005. Capreomycin is active against non-replicating M. tuberculosis. Ann. Clin. Microbiol. Antimicrob. 4:6.
13. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544. (Pubitemid 15211649)
14. Le Conte P, et al. 1994. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob. Agents Chemother. 38:2695-2701. (Pubitemid 24374423)
15. Lee SH, et al. 2003. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles. Int. J. Antimicrob. Agents 22:81-83. (Pubitemid 36808724)
16. Lehmann CR, et al. 1988. Capreomycin kinetics in renal impairment and clearance by hemodialysis. Am. Rev. Respir. Dis. 138:1312-1313. (Pubitemid 18264508)
17. Magazine R, Pal M, Chogtu B, Nayak V. 2010. Capreomycin-induced optic neuritis in a case of multi-drug resistant pulmonary tuberculosis. Indian J. Pharmacol. 42:247-248.
18. Miller J, Popplewell A, Landwehr A, Greene M. 1966. Toxicology studies in patients on prolonged therapy with capreomycin. Ann. N. Y. Acad. Sci. 135:1047-1056.
19. O'Brien RJ. 1993. The treatment of tuberculosis, p 207-240. In Reichman LB, Hershfield ES (ed), Tuberculosis: a comprehensive international approach. Marcel Dekker, New York, NY.
20. Organick AB, Wilson EM. 1968. Multiple drugs in retreatment of chronic pulmonary tuberculosis. Results with capreomycin and ethambutol. Dis. Chest 53:560-570.
21. Tuberculosis (Edinburgh, Scotland). 2008. Capreomycin. Tuberculosis (Edinb.) 88:89-91.
22. WHO. 2011. Guidelines for the programmatic management of drugresistant tuberculosis. 2011 update. WHO Document Production Services, Geneva, Switzerland.